• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2009
      • 7.1.1.3 2010
      • 7.1.1.4 2001
      • 7.1.1.5 2002
      • 7.1.1.6 2003
      • 7.1.1.7 2004
      • 7.1.1.8 2005
      • 7.1.1.9 2006
      • 7.1.1.10 2007
      • 7.1.1.11 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

The Expansion Continues: Merz Invests an Additional Million Euro Sum in Dessau

Frankfurt am Main, 26.07.2007

The pharmaceutical company Merz has invested a further million Euro sum in its production location in Dessau, Germany. The groundbreaking for the production facilities was already held in April of 2007, representing the Frankfurt company's largest single investment-to-date of 17.7 million Euros. Merz would like to use the new investment amount to integrate a parenterals pilot plant into the newly planned facility.

"The new pilot plant will promote the optimization of our processes and the manufacture of clinical prototypes for various dosage forms of parenteral pharmaceuticals," says Dr. Bernd Dölle, Head of the Reinheim and Dessau plants at Merz Group Services.

Parenteral dosage forms are sterile preparations that are intended for injection, infusion, or implantation in the human body. The company produces the active ingredient botulinum neurotoxin type A, a product of its own research, as well as the finished pharmaceutical product at its location in Dessau. In addition to the already-standing biotechnology facilities for active ingredient production, the parenteral pilot plant will round out the palette of production and process optimization functions for final, parenteral pharmaceutical dosage forms at the location.

"This investment is a deliberate step in the optimal utilization of the preexisting infrastructure," Dölle states. The date of completion for the entire facility is planned for August of 2008.

The botulinum neurotoxin type A has been approved since May of 2005 for use with the indications blepharospasm (dystonia of the eyelid) and cervical dystonia of a predominately rotational form (spasmodic torticollis, wryneck) in Germany. Approvals for use in Denmark and Sweden have also been issued to the company. Approval for further European countries should follow within the year.
Outside of Europe, use with these indications is also approved in Argentina and Mexico. In Argentina, the preparation is approved for further use in aesthetic dermatology for the temporary improvement of glabellar frown lines.

About Merz

Merz specializes in drugs for the treatment of neurological and psychiatric illnesses and is a leader in the field of Alzheimer's research. Merz developed Memantine, the world's first drug for the treatment of moderate to severe stages of Alzheimer's disease. Among drugs to combat Alzheimer's, Memantine is the second-largest in the world. Another area of competence at Merz is clinical and cosmetic dermatology.
Along with the pharmaceuticals market, Merz is active in the healthcare sector outside of pharmacies as well. With its tetesept® and Merz Spezial® brands, in German-speaking countries Merz is a leading provider of products for self-medication, dietary supplements, beauty and wellness.
A Merz subsidiary, Senator GmbH & Co. KGaA, is one of the leading manufacturers of high-quality promotional writing instruments worldwide.

The Merz Group employs 1,900 employees worldwide. The company achieved revenues of € 475 million in the 2005/06 fiscal year.

Download

Press Release

Your contact person:

Merz GmbH & Co. KGaA
Susanne Heiss
Corporate Communications
Eckenheimer Landstraße 100
60318 Frankfurt
Phone: +49 (0)69 / 15 03 - 411
Fax: +49 (0)69 / 15 03 - 581
E-Mail: susanne.heiss@merz.de

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s